Pharmacokinetics and clinical results of the new aza-anthracenedione BBR2778 in patients with advanced nonhodgkin lymphomas.

被引：0
|
作者：
Borchmann, P
Knippertz, R
Schnell, R
Camboni, G
Bernareggi, A
Diehl, V
Engert, A
机构：
[1] Univ Cologne, Innere Med Klin 1, Cologne, Germany
[2] Novuspharma, Monza, Italy
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4364
引用
收藏
页码：258B / 258B
页数：1
相关论文
共 7 条
  • [1] Phase-I study of BBR2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin lymphomas.
    Borchmann, P
    Knippertz, R
    Schnell, R
    Gamba, E
    Diehl, V
    Engert, A
    BLOOD, 1998, 92 (10) : 234B - 234B
  • [2] Activity and safety of the new aza-anthracenedione BBR 2778 in patients with relapsed non-Hodgkin lymphomas.
    Borchmann, P
    Morschhauser, F
    Schnell, R
    Kutz, K
    Barbieri, P
    Camboni, GM
    Engert, A
    BLOOD, 2002, 100 (11) : 303B - 303B
  • [3] Phase-II study of BBR 2778, a new aza-anthracenedione, in patients with relapsed aggressive non-Hodgkin lymphomas.
    Borchmann, P
    Morschhauser, F
    Schnell, R
    Harousseau, JL
    Gisselbrecht, C
    Rudolph, C
    Wilhelm, M
    Derigs, H
    Kutz, K
    Leynardier, D
    Verdi, E
    Camboni, G
    Engert, A
    BLOOD, 2001, 98 (11) : 341A - 341A
  • [4] Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas
    Borchmann, P
    Morschhauser, F
    Parry, A
    Schnell, R
    Harousseau, JL
    Gisselbrecht, C
    Rudolph, C
    Wilhelm, M
    Derigs, HG
    Pfreundschuh, M
    Camboni, G
    Engert, A
    HAEMATOLOGICA, 2003, 88 (08) : 888 - 894
  • [5] Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma
    Borchmann, P
    Schnell, R
    Knippertz, R
    Staak, JO
    Camboni, GM
    Bernareggi, A
    Hübel, K
    Staib, P
    Schulz, A
    Diehl, V
    Engert, A
    ANNALS OF ONCOLOGY, 2001, 12 (05) : 661 - 667
  • [6] A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies
    Faivre, S
    Raymond, E
    Boige, V
    Gatineau, M
    Buthaut, X
    Rixe, O
    Bernareggi, A
    Camboni, G
    Armand, JP
    CLINICAL CANCER RESEARCH, 2001, 7 (01) : 43 - 50
  • [7] BBR2778 a new anthracenedione analogue with no preclinical cardiac toxicity: Results from 3 phases I studies.
    Faivre, S
    Borchmann, P
    Jodrell, D
    Camboni, G
    Bernareggi, A
    Raymond, E
    Imadalou, K
    Engert, A
    Diehl, V
    CLINICAL CANCER RESEARCH, 1999, 5 : 3795S - 3795S
1